303 | James P. Allison on Fighting Cancer with the Immune System

What It Covers

Nobel laureate James Allison explains how immunotherapy harnesses the body's T cells to fight cancer by blocking checkpoint molecules like CTLA-4 and PD-1, achieving 55% ten-year survival rates in metastatic melanoma previously fatal within months.

Key Questions Answered

• •Checkpoint blockade mechanism: CTLA-4 acts as a brake on T cell expansion during immune response. Blocking it with antibodies allows T cells to proliferate longer and attack tumors, then therapy stops and regulation returns to normal, creating lasting immunity without continuous treatment.
• •Metastatic melanoma survival transformation: Before 2011, metastatic melanoma patients had seven-month median survival with under 3% alive at five years. Combining CTLA-4 and PD-1 checkpoint inhibitors now achieves 55% ten-year survival in randomized trials across 1000+ patients in multiple countries.
• •Myeloid cell interference problem: Pancreatic cancer and glioblastoma resist T cell therapy because myeloid cells treat tumors as wounds requiring protection. Current research targets switching these cells from protective mode to helping T cells attack tumors, addressing the 45% non-responder gap.
• •Tumor invisibility mechanisms: Cancer cells evade immune detection by losing MHC molecules that display mutated proteins on cell surfaces, or by mutating gamma interferon receptors so T cells cannot signal them to stop dividing. Future therapies must enable T cells to kill at distance.
• •Personalized vaccine development: Genomic sequencing combined with MHC typing now enables prediction of which tumor mutations will be presented to immune system. Therapeutic vaccines can be designed in weeks using cassette frameworks developed during COVID-19 pandemic for individual patient tumor profiles.